Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + extracorporeal photopheresis
- Development stage
- Unknown
- Lead developer
- City of Hope Medical Center
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Extracorporeal
01
Overview
aldesleukin + extracorporeal photopheresis is an investigational combination therapy being evaluated by the City of Hope Medical Center for the treatment of steroid-refractory chronic graft-versus-host disease (cGVHD). Aldesleukin is a recombinant form of interleukin-2 (IL-2) that, when administered at low doses, selectively promotes the expansion and growth of T regulatory (Treg) cells, which are essential for maintaining immune tolerance and controlling the immune system's attack on host tissues. Extracorporeal photopheresis (ECP) is an immunomodulatory procedure where a patient's blood is treated outside the body with a photosensitizing agent and ultraviolet A light before being returned to the patient. This combination approach aims to synergistically increase the Treg cell population and improve symptoms in patients whose cGVHD has not responded to standard steroid treatments.
- Brand names
- Proleukin
- Other names
- low-dose aldesleukin + ECPIL-2 + ECPlow-dose IL-2 + extracorporeal photopheresis
02
Targets
IL2RB (IL-2 receptor beta chain)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on aldesleukin + extracorporeal photopheresis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + extracorporeal photopheresis.